Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Equities research analysts at William Blair reduced their Q3 2025 earnings estimates for shares of Medpace in a research report issued on Tuesday, February 11th. William Blair analyst M. Smock now forecasts that the company will earn $2.99 per share for the quarter, down from their prior forecast of $3.18. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $11.93 per share. William Blair also issued estimates for Medpace's Q4 2025 earnings at $2.93 EPS, FY2025 earnings at $12.12 EPS, Q1 2026 earnings at $3.38 EPS, Q2 2026 earnings at $3.44 EPS, Q3 2026 earnings at $3.50 EPS and Q4 2026 earnings at $3.57 EPS.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%.
MEDP has been the topic of several other research reports. TD Cowen reduced their price target on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research report on Wednesday, October 23rd. Robert W. Baird increased their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Finally, Baird R W downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of "Hold" and an average price target of $381.44.
Check Out Our Latest Analysis on MEDP
Medpace Stock Performance
Shares of NASDAQ MEDP traded down $2.24 during trading hours on Thursday, hitting $340.17. 299,085 shares of the stock were exchanged, compared to its average volume of 208,882. The company has a market cap of $10.57 billion, a PE ratio of 29.79, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. The company's fifty day simple moving average is $343.50 and its two-hundred day simple moving average is $348.07. Medpace has a 1-year low of $302.01 and a 1-year high of $459.77.
Hedge Funds Weigh In On Medpace
Several large investors have recently modified their holdings of MEDP. CWM LLC raised its stake in shares of Medpace by 82.6% during the third quarter. CWM LLC now owns 4,241 shares of the company's stock valued at $1,416,000 after acquiring an additional 1,918 shares during the last quarter. Exchange Traded Concepts LLC increased its position in shares of Medpace by 47.7% during the third quarter. Exchange Traded Concepts LLC now owns 2,981 shares of the company's stock worth $995,000 after buying an additional 963 shares during the period. Swedbank AB acquired a new stake in shares of Medpace during the third quarter worth $7,477,000. Vontobel Holding Ltd. increased its position in shares of Medpace by 137.3% during the third quarter. Vontobel Holding Ltd. now owns 1,424 shares of the company's stock worth $475,000 after buying an additional 824 shares during the period. Finally, Rheos Capital Works Inc. increased its position in shares of Medpace by 18.3% during the third quarter. Rheos Capital Works Inc. now owns 29,101 shares of the company's stock worth $9,714,000 after buying an additional 4,500 shares during the period. Institutional investors own 77.98% of the company's stock.
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Recommended Stories
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
